Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: relationship with Th17 cytokine profile
- 19 Downloads
Breast cancer (BC) is a health problem worldwide; there is evidence that inflammatory cytokines are increased in BC. Macrophage migration inhibitory factor (MIF) has multiple effects on immune cells, inflammation and cancer. Besides, in previous studies, contradictory and uncertain results have been presented on the implication of Th17 cytokine profile in BC. The aim of this study was to evaluate the plasma levels of MIF and the Th17 cytokine profile in BC and their association with their molecular subtypes and clinical stage. A total of 150 women with BC of Ella Binational Breast Cancer Study and 60 healthy women (HW) were evaluated in cross-sectional study. The molecular subtypes were identified by immunohistochemistry. The plasma levels of MIF were quantified by ELISA and Th17 cytokine profile by multiplex system. MIF and IL-17 were significantly increased in BC versus HW (11.1 vs. 5.2 ng/mL and 14.8 pg/mL vs. 2.5 pg/mL p < 0.001, respectively). Our analysis showed that both MIF and IL-17A were associated with increased risk of breast cancer (OR 3.85 CI 95% 1.98–7.50 and OR 4.51 95% 1.83–11.15, respectively), higher in aggressive subtypes Luminal B, HER2 and TN. Likewise, we observed positive correlation between MIF and IL-17A (p < 0.001). In addition, IL-17E was lower in BC versus HW (p <0.001). Likewise, we observed a positive correlation between MIF and IL-17A (p < 0.001). In conclusion, both MIF and IL-17A were associated with high risk for breast cancer and aggressive molecular subtypes.
KeywordsMIF Th17 Cytokine profile Molecular subtypes Breast cancer
The authors greatly appreciate the important contribution of Rogelio Troyo Sanroman for the statistical analysis.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This study was conducted conforming to the declaration of Helsinki and the research was approved by the ethical investigation, committee from each hospital and Universidad de Guadalajara (CI-9708).
Informed consent was obtained from each participant before enrolling in this study.
- 5.Kawczyk-krupka A, Bugaj AM, Latos W, et al. ALA-mediated photodynamic effect on apoptosis induction, and secretion of macrophage migration inhibitory factor (MIF) and of monocyte chemotactic protein (MCP-1), by colon cancer cells in normoxia and in hypoxia-like conditions in vitro. Photodiagnosis Photodyn Ther. 2014;S1572–1000:1–25. https://doi.org/10.1016/j.pdpdt.2014.12.013.Google Scholar
- 6.Ballesio L, Gigli S, Di Pastena F, et al. Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvant chemotherapy in patients with locally advanced breast cancer: correlation with tumor biological subtypes and pathological response after therapy. Tumor Biol. 2017;39(3):1010428317694540.CrossRefGoogle Scholar
- 15.Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3(10):791–800. http://www.nature.com/doifinder/10.1038/nri1200.
- 23.Lugrin J, Ding XC, Le Roy D, et al. Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation. Biochim Biophys Acta Mol Cell Res. 2009;1793(11):1749–58. https://doi.org/10.1016/j.bbamcr.2009.09.007.CrossRefGoogle Scholar
- 26.Bando H, Matsumoto G, Bando M et al. Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res. 2002;93(4):389–96. http://www.ncbi.nlm.nih.gov/pubmed/11985788.
- 30.Hwang SY, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther. 2019 (in Press).Google Scholar
- 40.Wang L-N, Cui Y-X, Ruge F, Jiang WG. Interleukin 21 and its receptor play a role in proliferation, migration and invasion of breast cancer cells. Cancer Genom Proteom. 2015;12(5):211–21. http://cgp.iiarjournals.org/content/12/5/211.